NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Steroid Treatment for Hypereosinophilic Syndrome

Phase 4

Completed

Conditions: Leukocyte Disorder
Eosinophilia
Hypereosinophilic Syndrome
Hematologic Diseases

Interventions: Drug: prednisone

First Posted Date: 2012-02-02

Last Posted Date: 2022-02-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 26

Registration Number: NCT01524536

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Live Lung Donor Cross-sectional Cohort Study

Completed

Conditions: Lung Transplantation

First Posted Date: 2012-02-02

Last Posted Date: 2017-03-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 192

Registration Number: NCT01524835

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

HIV Accelerated Liver Disease in Uganda

Completed

Conditions: Fibrosis

First Posted Date: 2012-02-02

Last Posted Date: 2020-01-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 786

Registration Number: NCT01524562

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi, Bethesda, Maryland, United States

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

Early Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Fluzone® Intradermal (Sanofi Pasteur Inc.)

First Posted Date: 2012-01-26

Last Posted Date: 2017-03-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT01518478

Locations: 🇺🇸
National Jewish Health, Denver, Colorado, United States

Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation

Phase 2

Terminated

Conditions: Kidney Transplant Recipients

Interventions: Drug: Tacrolimus (CNI) Withdrawal
Drug: Standard Immunosuppressive Therapy

First Posted Date: 2012-01-25

Last Posted Date: 2017-09-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT01517984

Locations: 🇺🇸
University Hospitals of Cleveland, Cleveland, Ohio, United States
🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

and more 8 locations

Phase 2a EBA Trial of AZD5847

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Drug: AZD5847
Drug: Ethambutol, isoniazid, pyrazinamide, rifampin

First Posted Date: 2012-01-24

Last Posted Date: 2018-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 75

Registration Number: NCT01516203

Locations: 🇿🇦
Task Clinical Research Centre, Ekurhuleni, Gauteng, South Africa

Associating Renal Transplantation With the ITN Signature of Tolerance

Completed

Conditions: Kidney Transplantation

First Posted Date: 2012-01-24

Last Posted Date: 2016-12-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 250

Registration Number: NCT01516177

Locations: 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 5 locations

Apheresis to Obtain Plasma and White Blood Cells in Malies

Withdrawn

Conditions: Malaria

First Posted Date: 2012-01-18

Last Posted Date: 2019-12-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01511601

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

Phase 1

Completed

Conditions: Dengue

Interventions: Biological: Placebo
Biological: TetraVax-DV Vaccine - Admixture TV003
Biological: TetraVax-DV Vaccine - Admixture TV005

First Posted Date: 2012-01-10

Last Posted Date: 2015-08-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 58

Registration Number: NCT01506570

Locations: 🇺🇸
University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
🇺🇸
Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
🇺🇸
Fletcher Allen Health Care (FAHC), General Clinical Research Center (GCRC), Burlington, Vermont, United States

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

Phase 2

Completed

Conditions: HIV Infection

Interventions: Drug: Maraviroc
Other: Emtricitabine placebo
Drug: Emtricitabine
Drug: Tenofovir disoproxil fumarate
Other: Tenofovir disoproxil fumarate placebo
Other: Maraviroc placebo

First Posted Date: 2012-01-06

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 594

Registration Number: NCT01505114

Locations: 🇺🇸
Weill Cornell Chelsea CRS, New York, New York, United States
🇺🇸
New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States
🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy